Sandra Rost
Roche (United States) · 35 works · 5,761 citations · h-index 9
Top works
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab
- Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade
- Developing biomarkers to predict benefit from HGF / MET pathway inhibitors
- Multiplexed ion beam imaging analysis for quantitation of protein expresssion in cancer tissue sections
- Clinical and research applications of multiplexed immunohistochemistry and in situ hybridization
- Impact of MET expression on outcome in BRAF V600E/K advanced melanoma
- SPEX: A modular end-to-end platform for high-plex tissue spatial omics analysis
- Synthetic Antigen Gels as Practical Controls for Standardized and Quantitative Immunohistochemistry
- Fibroblastic FLT3L supports lymph node dendritic cells in the interfollicular niche
- Erratum: Multiplexed ion beam imaging analysis for quantitation of protein expresssion in cancer tissue sections
- Preclinical evaluation of anti-MET antibodies for immunohistochemical staining.
- Dictionary of human intestinal organoid responses to secreted niche factors at single cell resolution
- Mass Spectrometry-Based Tissue Imaging of the Tumor Microenvironment
- VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8+ T-cell Immunity in the Tumor Microenvironment
- Spatial Profiling of Protein and RNA Expression in Tissue: An Approach to Fine-tune Virtual Microdissection
- Fibroblastic FLT3L supports lymph node dendritic cells in the interfollicular niche
- Abstract PR002: T cell engager therapy affects the spatial distribution and phenotype of T cells in the tumor microenvironment
- Data from VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8+ T-cell Immunity in the Tumor Microenvironment
- Supplementary Fig. 5 from VSIG4 Restricts Hepatocellular Carcinoma Control by Suppressing Tumor-Specific CD8+ T-cell Immunity in the Tumor Microenvironment